Covestor Ltd Buys 63 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Covestor Ltd raised its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 34.4% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 246 shares of the medical research company’s stock after acquiring an additional 63 shares during the quarter. Covestor Ltd’s holdings in IQVIA were worth $59,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of IQV. Canada Pension Plan Investment Board lifted its holdings in shares of IQVIA by 6.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock valued at $719,634,000 after purchasing an additional 211,653 shares during the last quarter. Lazard Asset Management LLC boosted its position in IQVIA by 0.9% during the first quarter. Lazard Asset Management LLC now owns 3,263,944 shares of the medical research company’s stock worth $825,416,000 after purchasing an additional 30,014 shares in the last quarter. Farallon Capital Management LLC grew its stake in IQVIA by 3.1% in the 2nd quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock valued at $618,046,000 after acquiring an additional 86,870 shares during the period. Capital Research Global Investors raised its position in shares of IQVIA by 7.2% during the 1st quarter. Capital Research Global Investors now owns 2,138,802 shares of the medical research company’s stock worth $540,882,000 after purchasing an additional 143,533 shares during the last quarter. Finally, Impax Asset Management Group plc raised its holdings in shares of IQVIA by 9.7% during the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock valued at $423,885,000 after acquiring an additional 157,809 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares of the company’s stock, valued at $4,812,302.88. This represents a 6.24 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.60% of the stock is currently owned by insiders.

IQVIA Stock Performance

Shares of NYSE IQV opened at $202.94 on Friday. The company has a 50-day simple moving average of $228.86 and a 200-day simple moving average of $228.77. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The company has a market cap of $36.83 billion, a PE ratio of 26.63, a price-to-earnings-growth ratio of 2.20 and a beta of 1.51. IQVIA Holdings Inc. has a 12 month low of $200.20 and a 12 month high of $261.73.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on IQV. Evercore ISI lowered their price objective on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Argus upgraded shares of IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Truist Financial lowered their target price on IQVIA from $286.00 to $265.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. Finally, UBS Group raised their target price on shares of IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Five investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $259.13.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.